Patents Assigned to Immunex
  • ACPL antibodies and methods of use thereof
    Patent number: 7270817
    Abstract: The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: September 18, 2007
    Assignee: Immunex Corporation
    Inventors: John E. Sims, Teresa L. Born
  • Methods of inhibiting platelet activation and recruitment
    Patent number: 7264809
    Abstract: The present invention provides soluble CD39 polypeptides and compositions, and methods for inhibiting platelet activation and recruitment in a mammal comprising administering a soluble CD39 polypeptide.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: September 4, 2007
    Assignees: Immunex Corporation, Cornell Research Foundation, Inc.
    Inventors: Richard B. Gayle, III, Aaron J. Marcus, Charles R. Maliszewski
  • Methods of treating inflammatory and/or autoimmune disease
    Patent number: 7261894
    Abstract: The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, the use of such polypeptides in cellular and immune reactions, the use of such polypeptides in screening for agonists or antagonists of IL-1 epsilon activity, and kits comprising such polypeptides.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: August 28, 2007
    Assignee: Immunex Corporation
    Inventors: John E Sims, Dirk E Smith
  • Kits containing rank polypeptides
    Patent number: 7262274
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: August 28, 2007
    Assignee: Immunex Corporation
    Inventor: Dirk M. Anderson
  • Inhibitory Pellino nucleic acids
    Patent number: 7250507
    Abstract: There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: July 31, 2007
    Assignee: Immunex Corporation
    Inventors: Timothy A. Bird, David J. Cosman, Xiaoxia Li
  • Human IL-1 epsilon DNA and polypeptides
    Patent number: 7250276
    Abstract: The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in cellular and immune reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, and kits comprising these reagents.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: July 31, 2007
    Assignee: Immunex Corporation
    Inventors: John E Sims, Dirk E Smith
  • IL-1 zeta, IL-1 zeta splice variants and Xrec2 DNAs and polypeptides
    Publication number: 20070172456
    Abstract: The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.
    Type: Application
    Filed: March 13, 2007
    Publication date: July 26, 2007
    Applicant: Immunex Corporation
    Inventors: John Sims, Dirk Smith, Teresa Born
  • BTL-II proteins
    Patent number: 7244822
    Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: July 17, 2007
    Assignee: Immunex Corporation
    Inventors: Peter R. Baum, Sabine S. Escobar, Joanne L. Viney
  • Trimeric macrophage scavenger receptor fusion proteins and encoding nucleic acids
    Patent number: 7238499
    Abstract: The present invention relates, in part, to a polypeptide domain having reduced immunogenicity that is capable of inducing trimers in heterologous polypeptides, fusion polypeptides comprising the trimer inducing domain, nucleic acids encoding the polypeptides of the invention and methods of making and using the same.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: July 3, 2007
    Assignee: Immunex Corporation
    Inventor: Pranhitha Reddy
  • IL-1 eta DNA and polypeptides
    Patent number: 7235637
    Abstract: The invention is directed to novel, purified and isolated IL-1 eta polypeptides and fragments thereof, the polynucleotides encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived from these polypeptides, and uses thereof.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: June 26, 2007
    Assignee: Immunex Corporation
    Inventors: John E. Sims, Blair R. Renshaw
  • CD30 ligand
    Patent number: 7232660
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: June 19, 2007
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage
  • IL-18 receptors
    Publication number: 20070135625
    Abstract: A novel polypeptide that functions as an IL-18 receptor is disclosed. The receptor is multimeric and includes at least one AcPL polypeptide, or fragment thereof, and at least one IL-1Rrp1 polypeptide, or fraction thereof. The receptor binds IL-18 and finds use in inhibiting biological activities mediated by IL-18.
    Type: Application
    Filed: January 29, 2007
    Publication date: June 14, 2007
    Applicant: Immunex Corporation
    Inventors: John Sims, Teresa Born
  • IL-1 eta DNA and polypeptides
    Patent number: 7223565
    Abstract: The invention is directed to novel, purified and isolated IL-1 eta polypeptides and fragments thereof, the polynucleotides encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived from these polypeptides, and uses thereof.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: May 29, 2007
    Assignee: Immunex Corporation
    Inventors: John E. Sims, Blair R. Renshaw
  • Nectin polypeptides, polynucleotides, methods of making and use thereof
    Publication number: 20070117754
    Abstract: This invention relates to nectin polypeptides and polynucleotides, to methods of making such polypeptides and polynucleotides, and to methods of using such polypeptides and polynucleotides to modulate cell adhesion, cell migration, and angiogenesis, to treat conditions related to cell adhesion including endothelial and epithelial cell proliferation, migration, and barrier function, and to identify agents that alter nectin polypeptide activities.
    Type: Application
    Filed: December 13, 2006
    Publication date: May 24, 2007
    Applicant: Immunex Corporation
    Inventors: Peter Baum, William Fanslow, Timothy Lofton, Eric Sorensen, Adel Youakim
  • Nucleic acids encoding human adamalysin SVPH1-8
    Patent number: 7217553
    Abstract: The disclosure provides purified and isolated SVPH1–8 polypeptides, nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against such polypeptide, and fragmented peptides derived from these polypeptide. In addition, the disclosure provides uses of such polypeptides, fragmented peptides, antibodies and nucleic acids as well as kits containing the foregoing.
    Type: Grant
    Filed: October 3, 2002
    Date of Patent: May 15, 2007
    Assignee: Immunex Corporation
    Inventor: Douglas P. Cerretti
  • Polynucleotide encoding IL-1 zeta, TDZ.1 isoform polypeptide
    Patent number: 7217540
    Abstract: The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: May 15, 2007
    Assignee: Immunex Corporation
    Inventors: John E. Sims, Dirk E. Smith, Teresa L. Born
  • Viral encoded semaphorin protein receptor DNA and polypeptides
    Patent number: 7214497
    Abstract: The invention is directed to VESPR polypeptides as a purified and isolated protein, the DNA encoding the VESPR polypeptide, host cells transfected with cDNAs encoding VESPR, and methods for preparing VESPR polypeptides.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: May 8, 2007
    Assignee: Immunex Corporation
    Inventors: Melanie K. Spriggs, Michael R. Comeau, Robert F. DuBose, Richard S. Johnson
  • 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
    Patent number: 7211259
    Abstract: Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.
    Type: Grant
    Filed: August 5, 1997
    Date of Patent: May 1, 2007
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith
  • Cytokine polypeptides
    Publication number: 20070081973
    Abstract: This invention relates to IMX129840 cytokines, including new mammalian cytokine polypeptides; to methods of making such polypeptides; to methods of using them to treat conditions and diseases involving proliferation and/or differentiation of cells from pluripotent stem cell precursors; and to methods of identifying compounds that alter IMX129840 cytokine polypeptide activities.
    Type: Application
    Filed: November 20, 2006
    Publication date: April 12, 2007
    Applicant: Immunex Corporation
    Inventors: Peter Baum, Bruce Mosley, Randal Ketchem, Scott Taylor
  • Antibodies that bind TNF-? converting enzyme
    Patent number: 7199224
    Abstract: A metalloprotease that converts TNF-? from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: April 3, 2007
    Assignee: Immunex Corporation
    Inventors: Roy A Black, Charles Rauch, Carl J March, Douglas P Cerretti